Virologic Expands Pact With Pfizer

pfizer Inc. has signed an expanded agreement with Inc. to use ViroLogic’s HIV resistance testing technology for Pfizer’s HIV drug discovery and development programs. said the new pact covers work performed for all of Pfizer’s global research and development sites worldwide.

As recommended by the FDA’s antiviral drugs advisory committee, biopharmaceutical companies are using HIV resistance testing technology to enhance next-generation HIV drug development. The industry currently has 16 approved HIV drugs and another 40 new drugs in the pipeline, all of which will require resistance testing for their development.

ViroLogic’s patented technology can be applied to new HIV drug targets and is being further modified for use in vaccine research and development.

Online Steroids

Generic drug giant Dragon Pharma is offering: